Added to YB: 2025-11-17
Pitch date: 2025-11-14
NXGL [neutral]
NEXGEL, Inc.
-15.87%
current return
Author Info
Ahead of the Curve focuses on identifying and owning great small cap companies. Sign up for the newsletter.
Company Info
NEXGEL, Inc. manufactures and sells high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States.
Market Cap
$12.2M
Pitch Price
$1.89
Price Target
N/A
Dividend
N/A
EV/EBITDA
-6.74
P/E
-3.97
EV/Sales
1.27
Sector
Health Care Equipment and Supplies
Category
growth
NXGL: Disappointing Q3; exciting outlook for Q4 and beyond
NXGL (earnings): AbbVie partnership ended but was only call option, not core thesis. Expects 17-34% sequential Q4 growth via Silly George/contract manufacturing. STADA to 10x US line mid-2025. CEO targets EBITDA breakeven Q4, 5% margin 2025, 10% by 2027. Trading 1.3x TTM sales, 0.8x NTM, 5x 2027 EBITDA est despite 50%+ growth outlook, monopolistic niche position.
Read full article (2 min)